Equities

Genomtec SA

Genomtec SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)12.70
  • Today's Change0.04 / 0.32%
  • Shares traded17.08k
  • 1 Year change+27.77%
  • Beta--
Data delayed at least 15 minutes, as of May 07 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genomtec SA is a Poland-based company engaged in biotechnology and medical research business sector and it is operating in the field of clinical diagnostics. The Company is focused on development of of Genomtec ID, a mobile platform for genetic diagnosis in the point of patient care. Its creation and commercialization allows the diagnostic process to be executed in point of care setting, such as: primary care clinics, pharmacies, doctor’s offices, hospital emergency departments (ERs) without the need for complicated and time-consuming laboratory workflow conducted by qualified personnel.

  • Revenue in PLN (TTM)19.00k
  • Net income in PLN-13.35m
  • Incorporated2017
  • Employees--
  • Location
    Genomtec SAWroclawski Park Biznesu 3ul. Bierutowska 57-59WROCLAW 51-317PolandPOL
  • Websitehttps://genomtec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GENOMED SA22.48m996.34k39.11m--39.253.8624.221.740.75410.754117.017.662.006.2913.81--8.877.9010.249.3342.8538.564.433.934.103,257.61----9.853.87193.38-7.69-32.19--
Inventionmed SA610.00-2.46m42.08m9.00--7.85--68,980.88-0.0121-0.01210.000.02640.00002--0.000467.78-7.00-18.09-11.73-23.28-1,288.53-48.77-403,196.70-43,186.79---2.11-----85.01--88.90------
Medicofarma Biotech SA750.81k-2.67m54.38m----5.47--72.43-0.0393-0.03930.0110.14630.04683.571.51---16.65-13.16-21.54-15.8665.4529.92-355.88-37.810.6358-14.54-----82.34-31.48-68.11------
BioMaxima SA49.06m807.00k58.70m--79.071.1518.971.200.17710.177111.3712.140.67112.035.48--1.1018.571.2827.4044.5940.021.6413.160.84987.500.152--79.4635.74182.00104.6035.44--
BIOGENED SA95.56m4.20m59.44m205.0014.14--7.690.6221.711.7138.90--------466,145.20--2.92--4.1366.4268.044.403.31--3.68----20.0218.8824.3329.899.88--
Read Gene SA10.05m-1.85m63.67m11.00--14.43--6.33-0.1954-0.19541.060.37410.66648.814.51---12.24-1.71-13.14-2.1188.5788.01-18.37-3.906.46-4.19----38.7915.77-966.00------
Onesano SA13.09m-5.21m84.99m51.00--4.94--6.49-0.0812-0.08120.20830.26110.54491.986.21272,645.80-21.70-35.13-25.97--43.3852.79-39.83-32.033.40--0.0296--5.8030.63-225.52--14.67--
Urteste SA0.00-5.62m137.87m----4.78-----4.74-4.740.0020.470.00-------29.59---30.60----------30.77--0.0254------3.38------
Sds Optic SA530.40k-7.39m148.41m----21.16--279.80-1.30-1.300.09281.190.054-5.912.11---75.38---94.39--167.64---1,395.87--4.85--0.00---99.59---85.26------
Genomtec SA19.00k-13.35m155.18m----14.77--8,167.62-1.32-1.320.00180.8570.001424.230.0095---95.96---115.26---12,973.68---70,247.37--4.05-31.750.1413---81.72---126.20------
Poltreg SA1.40m-13.55m226.18m23.00--2.58--161.67-2.91-2.910.30018.770.011251.2227.4361,494.50-10.82-6.51-12.42-7.35-811.65-391.38-968.62-449.243.87--0.0856--40.04---588.92--214.26--
Data as of May 07 2024. Currency figures normalised to Genomtec SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.